1. Jochelson M. Breast cancer imaging: the future. Semin Oneol 2001;28:221-228. 2. Leung JW. New modalities in breast imaging: digital mam-mography, positron emission tomography, and sestamibi scin-timammography. Radiol Clin NorthAm 2002;40:467-482. 3. Koomen M, Pisano ED, Kuzmiak C, et al. Future directions in breast imaging. ] Clin Oneol2005;23: 1674-1677. 4. Hylton N. Magnetic resonance imaging of the breast: oppor-tunities to improve breast cancer management. ] Clin Oneol 2005;23: 1678-1684. 5. Rosen PP. Rosen's Breast Pathology. 3rd ed. Philadelphia, PA: Lippincott Williams &Wilkins; 2009. 6. Tavassoli FA. Normal development and anomalies. In: Tavassoli FA, ed. Pathology of the Breast. 2nd ed. Stamford, CT: Appelton &Lange; 1999:1-25. 7. Osborne MP. Breast anatomy and development. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:3-13. 8. McCarty KS, Nath M. Breast. In: Sternberg SS, ed. His-tology for Pathologists. Philadelphia, PA: Lippincott-Raven; 1997:71-82. 9. Anbazhagan R, Bartek J, Monaghan P, et al. Growth and development of the human infant breast. Am ] Anat 1991; 192:407-417. 10. Monaghan P, Perusinghe NP, Cowen P, et al. Peripubertal human breast development. Anat Ree 1990;226:501-508. 11. Going JJ,Moffat DF. Escaping from Flatland: clinical and biological aspects of human mammary duct anatomy in three dimensions. ] Pathol 2004;203:538-544. 12. Going JJ,Mohun TJ. Human breast duct anatomy, the "sick lobe" hypothesis and intraductal approaches to breast cancer. Breast Cancer Res Treat 2006;97:285-291. 13. Tot T.The theory of the sick breast lobe and the possible consequences. IntJ Surg Pathol 2007;15:369-375. 14. Jensen HM. Breast pathology, emphasizing precancerous and cancer-associated lesions. In: Bulbrook RO, Taylor DJ, eds. Commentaries on Research in Breast Disease. New York, NY: Alan R Liss; 1981:41-86. 15. Page DLAT. Diagnostic Histopathology of the Breast. Edin-burgh, Scotland: Churchill Livingstone; 1987. 16. Love SM, Barsky SH. Anatomy of the nipple and breast ducts revisited. Cancer 2004;101:1947-1957. 17. Rusby JE, Brachtel EF, Michaelson JS, et al. Breast duct anat-omy in the human nipple: three-dimensional patterns and clinical implications. Breast Cancer Res Treat 2007;106: 171-179. 18. Ohtake T, Kimijima I, Fukushima T, et al. Computer-assisted complete three-dimensional reconstruction of the mammary ductalllobular systems: implications of ductal anastomoses for breast-conserving surgery. Cancer 2001;91:2263-2272. 19. Schnitt SJ, Millis RR, Hanby AM, et al. The breast. In: Mills SE, ed. Diagnostic Surgical Pathology. 4th ed. Philadelphia, PA: Lippincott Williams &Wilkins; 2004:323-395. 20. Jarasch ED, Nagle RB, Kaufmann M, et al. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol 1988; 19:276-289. 21. Bocker W, Bier B, Freytag G, et al. An immunohistochemical study of the breast using antibodies to basal and luminal kera-tins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part I:normal breast and benign proliferative lesions. Virchows Arch APathol Anat Histopathol 1992;421:315-322. 22. Heatley M, Maxwell P, Whiteside C, et al. Cytokeratin inter-mediate filament expression in benign and malignant breast disease.] Clin Pathol 1995;48:26-32. 23. Bocker W,Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepi-thelial cell lineages: a new cell biological concept. Lab Invest 2002;82:737-7 46. 24. Abd EI-Rehim OM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma.] Pathol2004;203:661-67l. 25. YazijiH, Gown AM, Sneige N. Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol 2000;7: 100-109. 26. Barbareschi M, Pecciarini L, Cangi MG, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am] Surg Pathol2001 ;25: 1054-1060. 27. Moritani S, Kushima R, Sugihara H, et al.Availability of CD 10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 2002; 15:397-405. 28. Yeh IT, Mies C. Application of immunohistochemistry to breast lesions. Arch Pathol Lab Med 2008;132:349-358. 29. Bhargava R, Dabbs OJ. Use of immunohistochemistry in diagnosis of breast epithelial lesions. Adv Anat Pathol 2007; 14:93-107. 30. Popnikolov NK, Cavone SM, Schultz PM, et al. Diagnostic utility of p75 neurotrophin receptor as a marker of breast myoepithelial cells. Mod Pathol 2005; 18: 1535-154l. 3l. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of inva-sive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.32. Going JJ. Normal Breast. Philadelphia, PA: Churchill Livingstone/Elsevier; 2006. 33. Boecker W, Weigel S, Handel W, et al. The normal breast. In: Boecker W, ed. Preneoplasia of the Breast: ANew Conceptual Approach to Proliferative Breast Disease. Munich, Germany: Elsevier; 2006:2-27. 34. Cariati M, Purushotham AD. Stem cells and breast cancer. Histopathology 2008;52:99-107. 35. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature 2006;439:84-88. 36. Morimoto K, Kim SJ, Tanei T, et al. Stem cell marker alde-hyde dehydrogenase I-positive breast cancers are character-ized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Can-cer Sci 2009;100:1062-1068. 37. Zhou L, Jiang Y,Yan T, et al. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published lit-eratures. Breast Cancer Res Treat 2010;122:795-80l. 38. AI-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospec-tive identification of tumorigenic breast cancer cells. Proc NatlAcad Sci USA 2003;100:3983-3988. 39. Barsky SH, Siegal GP, Jannotta F, et al. Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 1983;49:140-147. 40. Wellings SR, Jensen HM, Marcum RG. Anatlas of subgross pathology of the human breast with special reference to possible precancerous lesions.] Natl Cancer Inst 1975;55:231-273. 41. Rosen PP. Multinucleated mammary stromal giant cells: a benign lesion that simulates invasive carcinoma. Cancer 1979;44: 1305-1308. 42. Russo J, Russo IH. Development of the human mammary gland. In: Neville MC, Daniel CW, eds. The Mammary Gland. Development, Regulation and Function. New York, NY: Plenum Press; 1987:67-93. 43. Russo J, Rivera R, Russo IH. Influence of age and parity on the development of the human breast. Breast Cancer Res Treat 1992;23:211-218. 44. Russo J, Romero AL, Russo IH. Architectural pattern of the normal and cancerous breast under the influence of parity. Cancer Epidemiol Biomarkers Prev 1994;3:219-224. 45. Russo J, Mills MJ, Moussalli MJ, et al. Influence of human breast development on the growth properties of primary cul-tures. In Vitro Cell Dev Biol 1989;25:643-649. 46. Baer HJ, Collins LC, Connolly JL, et al. Lobule type and sub-sequent breast cancer risk: results from the Nurses' Health Studies. Cancer 2009; 115: 1404-141l. 47. Milanese TR, Hartmann LC, Sellers TA, et al. Age-related lobular involution and risk of breast cancer.] Natl Cancer Inst 2006;98: 1600-1607. 48. Vogel PM, Georgiade NG, Fetter BF, et al. The correlation of histologic changes in the human breast with the menstrual cycle. Am] Pathol1981;104:23-34. 49. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am] Surg Pathol1986;10:382-393. 50. Ramakrishnan R, Khan SA, Badve S. Morphological changes in breast tissue with menstrual cycle. Mod Pathol 2002; 15:1348-1356. 5l. Anderson TJ. Normal breast: myths, realities, and prospects. Mod Pathol 1998; 11: 115-119. 52. Tavassoli FA, Yeh IT. Lactational and clear cell changes of the breast in nonlactating, nonpregnant women. Am] Clin Pathol 1987;87:23-29. 53. Toker C. Clear cells of the nipple epidermis. Cancer 1970;25:601-610. 54. Kohler S, Rouse RV, Smoller BR. The differential diagnosis of pagetoid cells in the epidermis. Mod Pathol 1998;11: 79-92. 55. Rosen PP, Tench W. Lobules in the nipple. Frequency and significance for breast cancer treatment. Pathol Annu 1985;20:317-322. 56. Schnitt SJ, Goldwyn RM, Slavin SA. Mammary ducts in the areola: implications for patients undergoing reconstructive surgery of the breast. Plast Reconstr Surg 1993;92:1290-1293. 57. Smith OM Jr, Peters TG, Donegan WL. Montgomery's areo-lar tubercle. A light microscopic study. Arch Pathol Lab Med 1982; 106:60-63. 58. Egan RL, McSweeney MB. Intramammary lymph nodes. Cancer 1983;51: 1838-1842. 59. Jadusingh IH. Intramammary lymph nodes. ] Clin Pathol 1992;45: 1023-1026. 60. Svane G, Franzen S. Radiologic appearance of nonpalpable intramammary lymph nodes. Acta Radiol 1993;34:577-580. 61. Oberman HA. Breast lesions confused with carcinoma. In: McDivitt R, Oberman H, Ozello L, eds. The Breast. Balti-more, MD: Williams &Wilkins; 1984: 1-3. 62. Battersby S, Anderson TJ. Proliferative and secretory activity in the pregnant and lactating human breast. Virchows Arch A PatholAnat HistopatholI988;413:189-196. 63. Battersby S, Anderson TJ. Histological changes in breast tissue that characterize recent pregnancy. Histopathology 1989; 15:415-419. 64. Hutson SW, Cowen PN, Bird CC. Morphometric studies of age related changes in normal human breast and their sig-nificance for evolution of mammary cancer. ] Clin Pathol 1985 ;38:281-287. 65. Cowan OF, Herbert TA. Involution of the breast in women aged 50-104 years: a histopathologic study of 102 cases. Surg PatholI989;2:323-333. 66. Rosen PP. Rosen's Breast Pathology. 2nd ed. Philadelphia, PA: Lippincott Williams &Wilkins; 2001. 67. Shoker BS, Jarvis C, Sibson DR, et al. Oestrogen receptor expression in the normal and pre-cancerous breast. ] Pathol 1999; 188:237-244. 68. Shaw JA, Udokang K, Mosquera JM, et al. Oestrogen recep-tors alpha and beta differ in normal human breast and breast carcinomas.] PathoI2002;198:450-457. 69. Shaaban AM, O'Neill PA, Davies MP, et al. Declining estro-gen receptor-beta expression defines malignant progression of human breast neoplasia. Am] Surg Pathol2003;27: 1502-1512. 70. Speirs V, Walker RA. New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast.] Pathol 2007 ;211:499-506. 71. Younes M, Honma N. Estrogen receptor beta. Arch Pathol Lab Med 2011 ;135:63-66. 72. Krishnamurthy S, Sneige N. Molecular and biologic mark-ers of premalignant lesions of human breast. Adv Anat Pathol 2002;9: 185-197.73. Siziopikou KP, Prioleau JE, Harris JR, et al. bcl-2 expres-sion in the spectrum of preinvasive breast lesions. Cancer 1996;77:499-506. 74. Egan MJ, Newman J, Crocker J, et al. Immunohistochemical localization of S 100 protein in benign and malignant condi-tions of the breast. Arch Pathol Lab Med 1987;111:28-31. 75. Earl HM, McIlhinney RA, Wilson P, et al. Immunohisto-chemical study of beta- and kappa-casein in the human breast and breast carcinomas, using monoclonal antibodies. Cancer Res 1989;49:6070-6076. 76. Bailey AJ, Sloane JP, Trickey BS, et al. An immunocyto-chemical study of alpha-lactalbumin in human breast tissue. ] PathoI1982;137:13-23. 77. Mazoujian G, Pinkus GS, Davis S, et al. Immunohistochem-istry of a gross cystic disease fluid protein of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am] Pathol 1983; 110: 105-112. 78. Sasaki E, Tsunoda N, Hatanaka Y,et al. Breast-specific expres-sion of MGBl/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of M G B 1-positive breast cancers. Mod PathoI2007;20:208-214. 79. Chui X, Egami H, Yamashita J, et al. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br ] Cancer 1996;73: 1233-1236. 80. Simone NL, Paweletz CP, Charboneau L, et al. Laser capture microdissection: beyond functional genomics to proteomics. Mol Diagn 2000;5:301-307. 81. Deng G, Lu Y, Zlotnikov G, et al. Loss of heterozygos-ity in normal tissue adjacent to breast carcinomas. Science 1996;274:2057-2059. 82. Lakhani SR, Chaggar R, Davies S, et al. Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. ] PathoI1999;189:496-503. 83. Larson PS, de las Morenas A, Cupples LA, et al. Genetically abnormal clones in histologically normal breast tissue. Am] Patho11998; 152: 1591-1598. 84. Larson PS, de las Morenas A, Bennett SR, et al. Loss of hetero-zygosity or allele imbalance in histologically normal breast epi-thelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am] Pathol2002;161:283-290. 85. Graham K, Ge X, de Las Morenas A, et al. Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically nor-mal breast epithelium. Clin Cancer Res 2011; 17:236-246. 86. Dontu G, Al-Hajj M, Abdallah WM, et al. Stem cells in normal breast development and breast cancer. Cell Prolif 2003;36:59-72. 87. Sgroi DC, Teng S, Robinson G, et al. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999;59: 5656-5661. 88. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc NatlAcad Sci USA 1999;96:9212-9217. 89. Emmett-Buck MR, Strausberg RL, Krizman DB, et al. Molecular profiling of clinical tissue specimens: feasibility and applications. Am] Pathol 2000; 156: 1109-1115. 90. Espina V, Geho 0,Mehta AI, et al. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005; 23:36-46.    